Enhertu plus pertuzumab wins EU first-line HER2-positive metastatic breast cancer approval

AstraZeneca said on 1 September 2026 that the EU approved Enhertu plus pertuzumab for first-line treatment of patients with HER2-positive metastatic breast cancer, and described the decision as the first new regimen in that setting in more than a decade ^[1].

What happened

The EU event is an approval, not a CHMP opinion, recommendation, or registry update: AstraZeneca announced on 1 September 2026 that Enhertu plus pertuzumab was approved for first-line treatment of patients with HER2-positive metastatic breast cancer ^[1]. FirstWord Pharma and The Pharma Letter also reported on 1 September 2026 that Europe cleared the Enhertu-pertuzumab combination in front-line HER2-positive breast cancer, but those items are secondary reporting in the dossier rather than primary regulatory records ^[2][3].

Enhertu is trastuzumab deruxtecan, and ChEMBL identifies trastuzumab deruxtecan as a HER2/erbB-2 binding agent ^[8]. Drugs@FDA lists ENHERTU under application BLA761139 with Daiichi Sankyo as the company ^[6]. The FDA label excerpt in the dossier describes ENHERTU as a HER2-directed antibody and topoisomerase inhibitor conjugate, which matters because the EU event moves an ADC-based regimen into the first-line metastatic HER2-positive breast cancer frame rather than leaving it only as a later-line competitive reference ^[7].

The supplied dossier did not include the European Commission decision document, EPAR, final EU label wording, pivotal trial identifier, efficacy table, hazard ratio, response rate, safety table, or exact regulatory basis for the EU approval. That gap is operationally material: the approval is established from AstraZeneca’s announcement ^[1], but Prognyx could not confirm the exact EU label language or the dataset supporting the decision from the supplied source set as of this briefing.

Why it matters

The signal is the move of T-DXd plus pertuzumab into EU first-line HER2-positive metastatic breast cancer ^[1], which puts an ADC-containing regimen directly into the treatment window where many competitors still position HER2 antibodies, HER2 ADCs, tyrosine-kinase combinations, and pertuzumab-containing backbones ^{[1][13][14][15][16]}. The phrase “first new regimen in more than a decade” comes from AstraZeneca’s release, so it should be treated as company-characterized market context rather than an independently reconstructed guideline history in this dossier ^[1].

Because the approved regimen is ADC-based, the competitive read extends beyond antibody-only comparators to ADC sequencing and payload and linker differentiation questions ^[7]. ADC reviews in the dossier describe antibody-drug conjugates as therapies that combine monoclonal-antibody target specificity with small-molecule payload cytotoxic potency through linkers, and they describe ADCs as a clinically validated component of modern precision oncology ^[9][10]. A separate 2026 Molecular Cancer Therapeutics article states that HER2-directed ADCs such as ENHERTU, also named DS-8201, represent a major therapeutic advance, while acquired resistance remains a significant clinical challenge ^[11].

That creates two strategic reads for competitors ^[1][11]. First, programs trying to improve on HER2 blockade without an ADC payload must now explain why a non-ADC regimen is clinically preferable against an approved ADC-plus-pertuzumab option in the first-line metastatic setting ^[1][7]. Second, next-wave ADCs must decide whether their differentiation story is payload, linker, target geometry, sequencing, retreatment, or tolerability, because a first-line Enhertu-containing regimen could compress the room for later-line-only positioning if EU practice adopts the regimen and later-line eligibility increasingly includes prior T-DXd exposure ^[1][10][11].

Who is exposed

The most direct exposure in the dossier sits with programs that touch the same first-line HER2-positive metastatic setting, pertuzumab combinations, or T-DXd-containing arms ^{[13][14][15][16]}. Sichuan Baili is exposed because NCT06445400 is a Phase 2 HER2-positive unresectable locally advanced or metastatic breast cancer study testing BL-M07D1 alone, BL-M07D1 plus pertuzumab, and BL-M07D1 plus pertuzumab plus docetaxel, placing another breast cancer ADC strategy near the same pertuzumab-combination question ^[13]. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin is exposed because NCT07003074 is a Phase 3 recurrent or metastatic HER2-positive breast cancer study comparing TQB2102 against docetaxel plus trastuzumab plus pertuzumab, making the comparator and line-of-therapy question directly relevant ^[14].

Shanghai JMT-Bio is exposed because NCT05838066 is a Phase 3 first-line HER2-positive recurrent or metastatic breast cancer study of KN026 plus HB1801 with pertuzumab and trastuzumab listed among interventions, which puts the program in the same first-line metastatic HER2-positive arena now affected by the EU approval ^[15]. Shanghai Henlius is exposed because NCT07294508 is a Phase 2/Phase 3 HER2-positive recurrent or metastatic breast cancer study testing HLX87 plus HLX22, HLX87 plus pertuzumab, T-DXd plus pertuzumab, and THP, so the trial record explicitly contains both T-DXd plus pertuzumab and the established antibody-taxane combination as treatment strategies ^[16].

The next tier is sequencing exposure, not same-line substitution ^[17][22]. Roche is exposed through NCT07413939, a Phase 2/Phase 3 trial of RO7771950 versus tucatinib with trastuzumab and capecitabine in locally advanced or metastatic breast cancer that is human epidermal growth factor receptor 2 positive; Prognyx’s read is that the risk is sequencing, because a first-line ADC-plus-pertuzumab approval can alter the assumptions feeding later-line HER2 studies ^[17]. Seagen, now a wholly owned subsidiary of Pfizer, is exposed because NCT03975647 is a Phase 3 advanced or metastatic HER2-positive breast cancer study of tucatinib versus placebo in combination with T-DM1, making HER2 sequencing after ADC-containing first-line therapy a central competitive question ^[22].

The comparator-adjacent tier is narrower: the dossier supports breast cancer ADC-versus-ADC or T-DM1-comparator relevance, not necessarily same-line HER2-positive metastatic eligibility for every record ^[18][19][21]. Jiangsu HengRui is exposed because NCT07497386 is a Phase 2 unresectable locally recurrent or metastatic breast cancer study listing trastuzumab rezetecan and trastuzumab deruxtecan, creating breast cancer ADC-versus-ADC relevance in the same broad disease setting ^[18]. CSPC ZhongQi is exposed because NCT06313086 is a Phase 3 HER2-positive advanced breast cancer study of DP303c versus trastuzumab emtansine, and DualityBio is exposed because NCT06265428 is a Phase 3 breast cancer study comparing DB-1303/BNT323 versus T-DM1 ^[19][21].

The registry landscape states what these companies are testing, not how well the agents work ^{[13][14][15][16][17][18][19][21][22]}. No efficacy conclusion about any competitor follows from these ClinicalTrials.gov listings alone ^{[13][14][15][16][17][18][19][21][22]}.

What to watch next

The next future registry date highlighted in this dossier is NCT07683754’s listed 4 September 2026 start date ^[4]. NCT07683754 is a Phase 3 advanced breast cancer, metastatic breast cancer, HER2-positive study that is not yet open and evaluates a structured sequential strategy starting with T-DXd plus pertuzumab upfront therapy, followed by maintenance dual HER2 blockade plus endocrine therapy plus palbociclib and potential T-DXd retreatment after progression under maintenance ^[4]. NCT07683754 lists planned enrollment of 200, a start date of 4 September 2026, a primary completion date of 4 July 2030, and a primary outcome of progression-free survival rate at 24 months ^[4].

NCT07683754 is important because it asks the question the approval leaves behind: whether first-line T-DXd plus pertuzumab should be treated as a one-time induction regimen, the first step in a planned maintenance architecture, or a drug that can be reintroduced after progression under maintenance ^[4]. The 4 July 2030 primary completion date is not a readout date, regulatory decision date, or verdict; it is the primary completion date listed for the trial ^[4].

The clearest feasibility warning in the dossier is NCT05744375, a Phase 2 first-line HER2-positive locally advanced or metastatic breast cancer study of trastuzumab deruxtecan in patients resistant to trastuzumab plus pertuzumab plus taxane due to early relapse ^[5]. That trial terminated early due to insufficient accrual, included two patients, and posted results including an objective response rate of one participant, time to treatment response of 1.9 months, and progression-free survival, overall survival, and duration of response values listed as not available ^[5]. No efficacy conclusion can be drawn from two patients in a prematurely terminated study ^[5].

The now-what

Option one: HER2 ADC companies should audit the named HER2-positive metastatic, pertuzumab/T-DXd-arm, sequencing, and T-DM1-comparator protocols in this dossier against a world in which T-DXd plus pertuzumab can be used first line in the EU ^{[1][13][14][18][19][21]}. The immediate questions are whether eligibility, stratification, prior-therapy definitions, and comparator assumptions still capture patients who may now receive an ADC-containing regimen before later-line entry ^{[1][13][18][19][21]}.

Option two: pertuzumab-combination competitors should make sequencing the core of the development story rather than treating pertuzumab as background therapy ^{[1][13][14][16]}. If T-DXd plus pertuzumab becomes the EU first-line reference point, trials containing pertuzumab, trastuzumab, docetaxel, THP, or T-DXd plus pertuzumab need a clear answer on whether they are replacing induction, improving maintenance, enabling retreatment, or preserving later-line efficacy ^{[1][4][13][14][16]}.

Option three: BD teams should separate direct threats from adjacent noise ^{[13][14][15][16][17][18][19][21][22]}. The directly exposed names in this dossier split into three groups: direct same-setting or pertuzumab/T-DXd-arm sponsors such as Sichuan Baili, Chia Tai Tianqing, Shanghai JMT-Bio, and Shanghai Henlius; sequencing-exposed HER2 studies from Roche and Seagen/Pfizer; and comparator-adjacent breast cancer ADC or T-DM1-comparator studies from Jiangsu HengRui, CSPC, and DualityBio ^{[13][14][15][16][17][18][19][21][22]}.

What remains unverified is the exact EU label text, pivotal dataset, efficacy magnitude, safety language, and regulatory basis for the approval, because the dossier supplies AstraZeneca’s announcement ^[1] and secondary reporting ^[2][3] but not EMA or European Commission authorization documents. The approval event is established by AstraZeneca’s announcement ^[1]; because the supplied dossier lacks the EU label and efficacy table, Prognyx cannot quantify clinical displacement from this packet alone.

Verdict: a credible protocol-review trigger for HER2-positive metastatic breast cancer programs that depend on non-ADC first-line positioning or post-ADC sequencing — same first-line EU setting, pertuzumab/T-DXd overlap, and T-DM1/tucatinib sequencing exposure — not yet a quantified clinical-displacement call, with a review window starting now and the next dated public checkpoint in this dossier on 4 September 2026 for NCT07683754 opening and 4 July 2030 for its listed primary completion date ^[1][4].